Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc.
The interactions between these components, which are divided into anti-tumor and pro …

In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …

Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early
results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT …

Tumors evade immune-mediated recognition through multiple mechanisms of immune
escape. On chronic tumor antigen exposure, T cells become dysfunctional/exhausted and …

White adipose tissue (WAT) is an essential regulator of energy storage and systemic
metabolic homeostasis. Regulatory networks consisting of immune and structural cells are …

Naive T cells are actively maintained in a quiescent state that promotes their survival and
persistence. On antigen stimulation, T cells exit quiescence to initiate clonal expansion and …

The environment, diet, microbiota and body's metabolism shape complex biological
processes in health and disease. However, our understanding of the molecular pathways …

T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on
lymphocytes that was recently propelled under the spotlight as a major emerging target in …

T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory receptor expressed
on several types of lymphocytes. Efficacy of antibody blockade of TIGIT in cancer …

Although immunotherapeutics targeting the inhibitory receptors (IRs) CTLA-4, PD-1 or PD-
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …